Advertisement


Afsaneh Barzi, MD, PhD, on Disparities in Access to Screening and Treatment of GI Cancers

2021 Gastrointestinal Cancers Symposium

Advertisement

Afsaneh Barzi, MD, PhD, of the City of Hope Comprehensive Cancer Center and the University of Southern California, discusses reasons for the incomplete understanding of the molecular landscape of minority patients with cancer, lack of screening chief among them. This underrepresentation, Dr. Barzi says, is more marked in gastrointestinal malignancies than other solid tumors, and she recommends ways to improve the outlook.



Related Videos

Colorectal Cancer

Romain Cohen, MD, PhD, on Colon Cancer: Prognostic Value of Tumor Deposits

Romain Cohen, MD, PhD, of the Mayo Clinic and Sorbonne University, discusses a post-hoc analysis of phase III results from the CALGB/SWOG 80702 study, which showed that adding the number of tumor deposits, a negative prognostic factor, to the count of lymph node metastases may improve the accuracy of TNM staging (Abstract 10).

Pancreatic Cancer

Talia Golan, MD, on Pancreatic Cancer: Olaparib for BRCA-Mutated Disease

Talia Golan, MD, of the Oncology Institute, Sheba Medical Center, discusses phase III results from the POLO trial, which explored the question of whether maintenance olaparib could improve overall and progression-free survival for patients with germline BRCA-mutated metastatic pancreatic cancer (Abstract 378).

Gastroesophageal Cancer
Immunotherapy

Wasat Mansoor, MBChB, PhD, on Esophageal Cancer: Quality of Life With Pembrolizumab and Chemotherapy

Wasat Mansoor, MBChB, PhD, of The Christie NHS Foundation Trust, discusses phase III results from the KEYNOTE-590 trial, which showed no deterioration in health-related quality of life when pembrolizumab was added to chemotherapy in patients with metastatic and unresectable esophageal cancers (Abstract 168).

Neuroendocrine Tumors

Rocio Garcia-Carbonero, MD, on Treating Neuroendocrine Tumors of Nonpancreatic Origin With Octreotide Acetate and Axitinib

Rocio Garcia-Carbonero, MD, of Hospital Universitario 12 De Octubre, discusses results of the phase II/III AXINET trial, which showed that axitinib plus long-acting release octreotide improved overall response compared with placebo and octreotide in patients with advanced grade 1 or 2 extrapancreatic neuroendocrine tumors. However, no significant improvement in progression-free survival was observed (Abstract 360).

Gastrointestinal Cancer

Rutika Mehta, MD, MPH, on Gastric Cancer: Adjuvant Chemotherapy With S-1 and Docetaxel

Rutika Mehta, MD, MPH, of the H. Lee Moffitt Cancer Center and Research Institute, discusses the 3-year regression-free and overall survival results from the JACCRO study, which compared the efficacy of S-1, an oral prodrug of fluorouracil, vs S-1 plus docetaxel after curative resection of stage III gastric cancer (Abstract 159).

Advertisement

Advertisement




Advertisement